110963-63-8

Basic information

• Product Name: 1-(2-Ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole
• Synonyms: 1-(2-Ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole;1-(2-Ethoxyethyl)-2-(4-piperidinyl)-1H-benzimidazole;1-(2-ethoxyethyl)-2-(piperidin-4-yl)-1H-1,3-benzodiazole;1-(2-ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]iMidazole;1-(2-Ethoxyethyl)-2-(4-piperidinyl)-1H-benziMidazole HCl;Bilastine Intermediate 1;1-(2-ethoxyethyl)-2-piperidin-4-ylbenzimidazole;Bilasten intermediate 2
• CAS NO: 110963-63-8
• Molecular Formula: C₁₆H₂₃N₃O
• Molecular Weight: 273.37332
• EINECS: 1308068-626-2
• Mol File: 110963-63-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 452.238 °C at 760 mmHg
• Flash Point: 227.306 °C
• Appearance: /
• Density: 1.18
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.02±0.10(Predicted)
• CAS DataBase Reference: 1-(2-Ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole(110963-63-8)
• EPA Substance Registry System: 1-(2-Ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole(110963-63-8)

Safety Data

• Hazardous Substances Data: 110963-63-8(Hazardous Substances Data)

Usage

General Description

1-(2-Ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole is a chemical composition mainly known for its use in the realm of medicinal chemistry. However, specific details about its properties and potential applications are not abundantly available. The name itself indicates it contains a benzimidazole group, a common moiety in many drug molecules due to its versatile reactivity, resulting in a variety of biological activities. Furthermore, the structure also contains a piperidine ring, another signature functional group in medicinal chemistry and ethoxy-ethyl group contributing to its overall physicochemical properties. As with any chemical compound, careful handling under appropriate safety measures is essential.

Upstream product

• 498-94-2 isonipecotic acid 
• 95893-89-3 N-(β-ethoxyethyl)-o-phenylenediamine 
• 1181267-36-6 tert-butyl 4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate 
• 953071-73-3 tert-butyl 4-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate 
• 38385-95-4 2-(4-piperidinyl)-1H-benzimidazole 
• 95-54-5 1,2-diamino-benzene 
• 88-74-4 2-nitro-aniline 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 

Downstream Products

• 1181267-38-8 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidine]ethyl]-α,α-dimethylphenylacetic acid methyl ester 
• 202189-78-4 Bilastine 

Relevant articles and documents

Preparation method of bilastine important intermediate

According to the preparation method disclosed by the invention, the formula VI is prepared by reacting the formula V with bromoethyl ethyl ether, and a phase transfer catalyst tetrabutylammonium iodide is added, so that the reaction time is greatly shortened. the product of the formula VI is subjected to acid hydrolysis to obtain a compound II. The method is a good method for synthesizing the compound II, is mild in reaction condition, simple to operate and convenient to industrialize, and conforms to the development direction of green chemistry.

IMPROVED PROCESSES FOR PREPARATION OF BILASTINE USING NOVEL INTERMEDIATES

Provided herein are improved, commercially viable and industrially advantageous processes for the preparation of Bilastine or a pharmaceutically acceptable salt thereof using novel intermediates, in high yield and purity.

Discovery of Novel 2-(piperidin-4-yl)-1H-benzo[d]imidazole Derivatives as Potential Anti-Inflammatory Agents

A novel 2-(piperidin-4-yl)-1H-benzo[d]imidazole derivative 5 with good anti-inflammatory activity was identified from our in-house library. Based on hit compound 5, two series of 2-(piperidin-4-yl)-1H-benzo[d]imidazole derivative 6a-g and 7a-h were designed and synthesized as novel anti-inflammatory agents. Most of synthesized compounds exhibited good inhibitory activity on NO and TNF-α production in LPS-stimulated RAW 264.7 macrophages, in which the compound 6e showed most potent inhibitory activity on NO (IC50 = 0.86 μm) and TNF-α (IC50 = 1.87 μm) production. Further evaluation revealed that compound 6e displayed more potent in vivo anti-inflammatory activity than ibuprofen did on xylene-induced ear oedema in mice. Additionally, Western blot analysis revealed that compound 6e could restore phosphorylation level of IκBα and protein expression of p65 NF-κB in LPS-stimulated RAW 264.7 macrophages.